May 18 |
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
|
May 17 |
AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst
|
May 17 |
Robinhood upgraded, Baidu downgraded: Wall Street's top analyst calls
|
May 17 |
AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week®
|
May 16 |
AbbVie CEO latest heavy hitter to buy in Boca Raton
|
May 15 |
AbbVie, Inc. (ABBV) Bank of America Health Care Conference Call Transcript
|
May 15 |
NeuroSense taps PhaseV’s ML tech for Phase III ALS trial analysis
|
May 14 |
AbbVie (ABBV) Boosts Neuropsychiatric Portfolio With New Deal
|
May 14 |
3 Magnificent Stocks That Are Passive Income Machines
|
May 13 |
AbbVie, Gilgamesh to develop next-generation psychedelic drugs
|